RenovoRx Expands TAMP Platform into Borderline Resectable Pancreatic Cancer with PRISM-TAMP Trial Launch
Event summary
- First patient enrolled in PRISM-TAMP trial evaluating TAMP for borderline resectable pancreatic cancer.
- Trial sponsored by University of Vermont, targeting 10 patients with primary focus on tumor regression and surgical outcomes.
- RenovoRx's TAMP platform delivers gemcitabine via RenovoCath for neoadjuvant treatment before surgery.
- Phase III TIGeR-PaC trial completion expected in H1 2027 with topline data readout in H2 2027.
The big picture
RenovoRx's expansion into borderline resectable pancreatic cancer with the PRISM-TAMP trial marks a strategic shift from its current focus on locally advanced pancreatic cancer. This move aligns with broader industry trends toward targeted, localized therapies that aim to improve surgical outcomes and reduce systemic toxicities. The trial's success could position RenovoRx as a key player in the neoadjuvant treatment space, potentially opening new market opportunities beyond its current Phase III trial.
What we're watching
- Trial Execution
- Whether PRISM-TAMP can demonstrate improved local therapeutic response and surgical outcomes for borderline resectable pancreatic cancer.
- Regulatory Pathway
- The pace at which RenovoRx can leverage investigator-initiated trial data to expand TAMP applications beyond locally advanced pancreatic cancer.
- Commercialization Strategy
- How RenovoRx will balance IIT expansion with the completion of its Phase III TIGeR-PaC trial and potential commercialization of RenovoCath.
Related topics
